AI Detection for Cardiovascular Disease Prevention

(AI INFORM Trial)

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Brigham and Women's Hospital

Disqualifiers: Coronary artery disease, Cancer, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 1 Jurisdiction This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

1500 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if AI can identify coronary artery calcifications (CAC) on chest CT scans to help doctors start or adjust treatments that prevent heart problems. The AI tool, Nanox.AI Coronary Artery Calcification Assessment, analyzes CT scans and informs doctors about the presence of CAC, potentially improving preventive care. Participants should have had a chest CT scan in the last three years and should not have a history of heart disease or cancer. As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance heart disease prevention strategies.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that this AI platform is safe for cardiovascular disease prevention?

Research has shown that the Nanox.AI Coronary Artery Calcification Assessment helps identify heart disease risks by examining chest CT scans. Although the safety of this AI tool hasn't been tested on people like a new drug, it uses existing CT scans and doesn't introduce new physical risks to patients.

Nanox.AI's system has detected heart disease risks in many patients without any reported negative effects from the AI itself. The technology analyzes scan images and provides information to doctors, resulting in no additional side effects from using this software. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the AI Detection for Cardiovascular Disease Prevention trial because it uses cutting-edge AI technology to identify coronary artery calcification from chest CT scans. Unlike traditional methods that rely on manual interpretation by radiologists, this AI-based approach promises faster and potentially more accurate detection, helping doctors catch early signs of heart disease sooner. This could lead to timely interventions and personalized treatment plans, ultimately aiming to improve patient outcomes by preventing the progression of cardiovascular disease.

What evidence suggests that this AI platform is effective for detecting coronary artery calcifications?

Studies have shown that the Nanox.AI platform effectively detects calcium buildup in the heart's arteries, an early sign of heart disease. Research indicates that this AI tool identifies moderate to severe levels of this buildup in about 58% of patients. In this trial, one group will receive notification of coronary artery calcification detected by the AI, enabling doctors to start preventive treatments sooner, which may lead to better health outcomes. The other group will not receive notification. The AI technology not only finds these calcium buildups but also measures them, providing a detailed view of heart health risk. ^{1 3 4 6 7}

Are You a Good Fit for This Trial?

This trial is for individuals aged 40-75 who've had a chest CT scan in the last 3 years and have no history of coronary artery disease, cancer, or any other life-limiting conditions. It's aimed at enhancing cardiovascular disease prevention.

Inclusion Criteria

I am between 40-75 years old and had a chest CT scan in the last 3 years.

Exclusion Criteria

I do not have any other condition that could shorten my life.

I have had heart disease related to my arteries.

I have had cancer before.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Notification or non-notification of coronary artery calcification detected by AI, followed by recommendation or non-recommendation of preventive therapy

6 months

Follow-up

Participants are monitored for changes in LDL-C, initiation or intensification of preventive therapies, and occurrence of cardiovascular events

12 months

What Are the Treatments Tested in This Trial?

Interventions

• Nanox.AI Coronary Artery Calcification Assessment

Trial Overview

The AI INFORM study is testing if notifying clinicians about the presence and amount of calcium buildup in arteries using an AI tool (Nanox.AI) leads to better preventive care. This involves analyzing past chest CT scans without contrast.

How Is the Trial Designed?

Group I: Notification of Coronary Artery Calcification Experimental Treatment 1 Intervention

Notification to providers of the presence of coronary artery calcification automatically detected by AI based device (software) on chest CT. Recommendation of preventive therapy.

Group II: Non-notification of Coronary Artery Calcification Active Control 1 Intervention

No notification to providers of the presence of coronary artery calcification on chest CT automatically detected by AI based device (software) on chest CT. No recommendation of preventive therapy.

Who Is Running the Clinical Trial?

Brigham and Women's Hospital

Lead Sponsor

Trials

1,694

Recruited

14,790,000+

Nano-X Imaging Limited

Collaborator

Trials

1

Recruited

1,500+

Published Research Related to This Trial

In a study involving 25 patients, the reliability of scoring coronary artery calcium burden using CT scans showed significant interobserver and intraobserver disagreements, particularly on small lesions.

Despite these disagreements, the impact on the overall measures of calcium burden (calcium score, number of calcified lesions, and calcified area) was negligible, suggesting that multiple observers scoring the same CT exam may not be necessary.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Detection of heart calcification with electron beam CT: interobserver and intraobserver reliability for scoring quantification. Kaufmann, RB., Sheedy, PF., Breen, JF., et al.[2016]

A fully automated AI model for scoring coronary artery calcium (CAC) demonstrated high accuracy, correlating strongly with manual assessments, with a Spearman's correlation of 0.90 and an intraclass correlation coefficient of 0.98 based on 1849 cardiac CT scans.

The AI model was able to classify 89% of scans into the same risk categories as human experts, while significantly reducing analysis time to an average of just 13.1 seconds per scan, suggesting it could enhance clinical workflow efficiency.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evaluation of an artificial intelligence coronary artery calcium scoring model from computed tomography. Ihdayhid, AR., Lan, NSR., Williams, M., et al.[2023]

A deep learning system was developed to automatically quantify coronary artery calcium from routine CT scans, demonstrating strong predictive power for cardiovascular events in a study of 20,084 individuals across various cohorts.

The automated scoring system showed high correlation with manual quantification and robust reliability, suggesting it could effectively enhance clinical practice by streamlining the assessment of cardiovascular risk.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Deep convolutional neural networks to predict cardiovascular risk from computed tomography. Zeleznik, R., Foldyna, B., Eslami, P., et al.[2022]

The AI-based automatic coronary artery calcium (CAC) scoring software demonstrated excellent correlation and agreement with a semi-automatic method, with a Spearman correlation coefficient of 0.935 for Agatston score, indicating high reliability in measuring coronary artery health.

The automatic software was significantly faster, taking a median of 36 seconds compared to 59 seconds for the semi-automatic method, making it a more efficient option for clinical use in assessing cardiovascular risk.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evaluation of an AI-based, automatic coronary artery calcium scoring software. Sandstedt, M., Henriksson, L., Janzon, M., et al.[2021]

A new method using two convolutional neural networks can automatically detect calcifications in low-dose chest CT scans, which helps identify cardiovascular risks in heavy smokers, similar to lung cancer risks.

The method showed high reliability in detecting calcifications, achieving F1 scores up to 0.89 for coronary artery calcifications, indicating it can effectively assess cardiovascular risk in patients undergoing lung cancer screening.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Automatic Calcium Scoring in Low-Dose Chest CT Using Deep Neural Networks With Dilated Convolutions. Lessmann, N., van Ginneken, B., Zreik, M., et al.[2019]

Coronary calcifications are a key indicator of coronary heart disease (CHD) and their presence can help diagnose atherosclerotic disease in asymptomatic individuals with risk factors, potentially before any symptoms appear.

Calcium scoring using advanced imaging techniques like electron beam computed tomography (EBCT) and multi-slice CT allows for precise quantification of coronary calcifications, but the long-term prognostic value of these scores in asymptomatic high-risk patients is still uncertain.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Detection and quantification of coronary calcification: an update]. Fischbach, R., Heindel, W.[2016]

The gradient boosting machine (GBM) model demonstrated a remarkable sensitivity of 100% for predicting obstructive coronary artery disease (CAD) in a study of 435 patients, indicating it can effectively rule out the disease.

While the model showed high negative predictive value (100%), its positive predictive value was lower at 38%, suggesting that while it is excellent at identifying patients without CAD, it may not be as reliable in confirming the presence of the disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Machine Learning-based Algorithm Enables the Exclusion of Obstructive Coronary Artery Disease in the Patients Who Underwent Coronary Artery Calcium Scoring. Głowacki, J., Krysiński, M., Czaja-Ziółkowska, M., et al.[2020]

An AI model was developed to automatically quantify coronary artery calcium (CAC) using deep learning on ECG-gated cardiac CT images, trained on 560 images and validated on 409 additional images, achieving excellent accuracy with a Cohen's kappa of 0.95 in the test cohort.

The AI model demonstrated minimal differences in CAC scores compared to manual evaluations, indicating its potential for reliable and efficient assessment of coronary artery health, which could enhance clinical decision-making.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Fully automated coronary artery calcium quantification on electrocardiogram-gated non-contrast cardiac computed tomography using deep-learning with novel Heart-labelling method. Takahashi, D., Fujimoto, S., Nozaki, YO., et al.[2023]

A fully automated method for detecting coronary calcifications from non-contrast-enhanced CT scans achieved a detection rate of 73.8% for coronary calcifications with only 0.1 false positives per scan, demonstrating its efficacy in identifying potential cardiovascular risks.

The method successfully categorized 93.4% of scans into the correct risk categories based on computed calcium scores, indicating its potential for accurate risk assessment in patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Detection of coronary calcifications from computed tomography scans for automated risk assessment of coronary artery disease. Isgum, I., Rutten, A., Prokop, M., et al.[2019]

An AI-based automatic coronary artery calcium (CAC) scoring system demonstrated excellent reliability when compared to manual scoring in low-dose chest CT scans, with a high intraclass correlation coefficient (0.989) across a study of 452 subjects from three institutions.

While the AI system showed good performance overall, the reliability of CAC severity categorization varied among different datasets, indicating that results may differ based on the institution's imaging quality and conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Fully automatic coronary calcium scoring in non-ECG-gated low-dose chest CT: comparison with ECG-gated cardiac CT. Suh, YJ., Kim, C., Lee, JG., et al.[2023]

Citations

1.

nanox.vision

nanox.vision/ai-cardiac-solution/

AI Cardiac Solution - Nanox

Nanox.AI HealthCCSng algorithm identified moderate to severe levels of coronary artery calcium (CAC) in 58% of patients. Watch now. Close. Article. Cardiac ...

2.

investors.nanox.vision

investors.nanox.vision/news-releases/news-release-details/innovative-data-featuring-nanox-ai-cardiac-solution-showcased

Innovative Data Featuring Nanox AI Cardiac Solution ...

In a study conducted by Brigham & Women's Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients.

3.

blackfordanalysis.com

blackfordanalysis.com/ai-portfolio-nanoxai-cardiac-solution

Nanox AI Cardiac Solution HealthCCSng

Nanox AI detects coronary artery calcification (CAC) to help identify patients at risk of coronary artery disease.

4.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10702149/

Using Artificial Intelligence to Semi-Quantitate Coronary ...

Artificial intelligence (AI) algorithms can help detect and quantify CAC/ASCVD which can lead to early treatment and improved outcomes.

5.

accessdata.fda.gov

accessdata.fda.gov/cdrh_docs/pdf24/K241440.pdf

August 19, 2024 Nano-X AI Ltd. Neta Sherman Associate VP ...

The device generates an exact calcium score and a four coronary artery calcium detection category output representing the estimated quantity of.

6.

nanox.vision

nanox.vision/ai/

Nanox.AI

AI's cardiac solution, Corewell Health significantly increased their ability to detect coronary calcification, identifying nearly 4,000 new patients in 2023 ...

7.

finance.yahoo.com

finance.yahoo.com/news/data-supporting-nanox-ai-cardiac-120000481.html

Data Supporting Nanox.AI Cardiac Solution to Be ...

Nanox AI's Cardiac Solution (HealthCCSng) utilizes medical imaging data from routine chest CT scans to automatically quantify coronary artery ...